CYP-001 GvHD Trial Primary Evaluation Results
Open PDF
| Stock | Cynata Therapeutics Ltd (CYP.ASX) |
|---|---|
| Release Time | 17 Jun 2026, 12:05 p.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Cynata Therapeutics CYP-001 GvHD Trial Results
Key Points
- No safety concerns identified
- No significant differences in primary or key secondary endpoints
- Trial terminated early due to disappointing results
Full Summary
Cynata Therapeutics Limited (ASX: CYP) announced the primary evaluation results of its Phase 2 clinical trial of CYP-001 in patients with high-risk acute graft versus host disease (HR-aGvHD). The trial, which enrolled 65 patients across Australia, the USA, and Europe, found no safety concerns and no significant differences between the active and control groups in primary or key secondary endpoints. The trial was terminated early due to these disappointing results. Cynata will remain under voluntary suspension from the ASX pending the results of the Phase 3 SCUlpTOR trial of CYP-004 in patients with osteoarthritis of the knee.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In